Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jul 9;16(7):e0254488. doi: 10.1371/journal.pone.0254488

Vitamin D deficiency and severity of pneumonia in Indonesian children

Vicka Oktaria 1,2,3,4,*, Rina Triasih 4,5, Stephen M Graham 1,2, Julie E Bines 1,2, Yati Soenarto 4,5, Michael W Clarke 6, Mike Lauda 5, Margaret Danchin 1,2
Editor: Michal Zmijewski7
PMCID: PMC8270442  PMID: 34242372

Abstract

Objective

To determine the prevalence of vitamin D deficiency in Indonesian children hospitalized with pneumonia and evaluate the association between vitamin D status and severity of pneumonia.

Methods

A hospital-based cross-sectional study was conducted from February 2016 to July 2017 in two district hospitals in Yogyakarta province, Indonesia. Infants and young children aged 2–59 months hospitalized with pneumonia were recruited. Serum blood samples were collected on admission and analyzed for total serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 concentrations using liquid chromatography-tandem mass spectrometry. Vitamin D deficiency was defined as a level of serum vitamin D <50 nmol/L. The association between vitamin D deficiency and severity of hospitalized pneumonia according to WHO criteria, including the presence of danger signs, hypoxemia (SpO2 in air below 90%), duration of hospitalization, and admission to Intensive Care Unit (ICU), was analyzed using logistic regression.

Results

133 children with WHO-defined pneumonia were enrolled in the study and 127 (96%) had their vitamin D status determined. The mean vitamin D concentration was 67 (± 24 SD) nmol/L and 19% of participants were vitamin D deficient. Age younger than 6 months was associated with prolonged hospitalization (> 5 days) and low birth weight and poor nutritional status on admission were risk factors for hypoxemia. However, vitamin D status was not associated with the presence of danger signs, duration of hospitalization, or hypoxemia.

Conclusions

One in every five children hospitalized with pneumonia was vitamin D deficient. Vitamin D status was not associated with the severity of pneumonia.

Introduction

Micronutrient supplementation in children has an established role in public health and clinical management of pneumonia. The benefits of vitamin A supplementation, for example, have long been recognized for prevention of morbidity and mortality in young children (<5 years), and for improving clinical outcome for measles pneumonia [1,2]. Therefore, vitamin A supplementation is part of the Global Action Plan for Pneumonia and Diarrhea framework [3]. Zinc supplementation has also been shown in populations at risk of zinc deficiency to improve outcomes in children with diarrhea or pneumonia [4]. More recently, vitamin D supplementation has been considered as a potential strategy for the prevention and treatment of pneumonia [5,6] but evidence from countries with high burden of pneumonia are limited.

Pneumonia and vitamin D deficiency (defined as serum vitamin D level < 50 nmol/L) are common in Indonesian children [7,8]. Indonesia was ranked seventh among countries globally for the number of child pneumonia deaths by UNICEF in 2015 [3]. Community acquired pneumonia accounted for 18% of all hospitalizations in Indonesian children < 5 years with a case fatality rate between 5% and 20% [9]. Vitamin D deficiency has been reported common in one in every three to five Indonesian children aged between 6 months to 12 years old, and nine in every ten newborns [10,11].

Vitamin D modulates the immune and inflammatory response against infections [12]. A meta-analysis using individual participant data reported that vitamin D protected from all respiratory infections in adults and children [13]. Vitamin D deficiency at birth has also been associated with more frequent episodes of acute respiratory infections non pneumonia in the first year of life of Indonesian infants [11]. However, the potential role of vitamin D in reducing severity of lower respiratory tract infections, and thereby potentially improving outcomes and reducing hospitalizations, was not clear [13]. There was a limited number of vitamin D supplementation trials conducted in children hospitalized with pneumonia and findings were inconsistent [1416]. Evidence from observational studies as to whether or not vitamin D deficiency in young children with pneumonia is associated with more severe manifestations and clinical course have been contradictory and depends on the markers of severity used [1719]. Although vitamin D could be a simple and cheap intervention, WHO highlights the need for more clinical research to inform specific recommendation [20].

We aimed to determine the prevalence of vitamin D deficiency in infants and children aged 2 to 59 months hospitalized with pneumonia at two district hospitals in Indonesia, and to evaluate the association between vitamin D status and the severity and outcome of pneumonia.

Materials and methods

Study design, setting, and participants

We conducted a hospital-based cross-sectional study in two district hospitals in Yogyakarta province: Kota Yogyakarta hospital (RSUD Kota, an urban hospital) and Kulon Progo hospital (RSUD Wates, a rural hospital) from 1st February 2016 to 31st July 2017. All infants and children aged 2–59 months who were firstly admitted in one of the two study hospitals with pneumonia during the study period, were eligible for recruitment to the study.

Study procedures

Following written informed consent from the parent, on admission we documented the clinical characteristics of the child, symptoms and signs of pneumonia including the presence of danger signs, nutritional status, and peripheral oxygen saturation using a standard case report form (S1 File). Pneumonia was defined according to the revised WHO criteria of cough with fast breathing or chest indrawing, without danger signs [21]. Severe pneumonia was defined as pneumonia with any danger sign present including hypoxemia, inability to drink and feed, nasal flaring or grunting, persistent vomiting, lethargy, and convulsion [21]. Hypoxemia was defined as SpO2< 90% in room air. We defined prolonged hospitalization as duration of hospitalization of more than 5 days. This was based on the average length of five days hospital stay for pneumonia reported by Center for Disease Control and prevention (CDC) [22] and was in accordance with the minimum days for standard antibiotic therapy course for children hospitalized with pneumonia by WHO [21]. The similar definition has also been used by other study [23]. Undernutrition was defined by WHO definition: underweight for weight-for-age—3 SD to < -2 SD, stunted for height(or length)-for-age—3 SD to < -2 SD, and wasted for weight-for-height(or length) - 3 SD to < -2 SD. Severe undernutrition was defined as: severely underweight for weight-for-age < -3SD, severely stunted for height(or length)-for-age < -3SD, and severely wasted for weight-for-height(or length) <-3SD [24]. There is no consensus on the recommended serum vitamin D cut off for respiratory health. We defined vitamin D deficiency as a serum (or plasma) 25-hydroxyvitamin D (25(OH)D) concentrations < 50 nmol/L. This is the recommended cut off for optimal bone homeostasis [25]. In this paper, we mainly used < 50 nmol as the cut-off for deficiency but different cut off levels (< 75 nmol/L and < 25 nmol/L) were also tested in our analysis.

A parent-interview questionnaire was completed to collect information on the baseline characteristics, including the potential risk factors for severe pneumonia (e.g., birth weight, prematurity, household crowding, childcare attendance, early solid food, indoor pollution) (S1 File). On the day of admission, a complete blood count test and a chest radiograph were performed. An extra specimen of 2.5 mls of venous blood was collected within day 1 to 3 days of hospitalization for a vitamin D assay at the time of routine blood collection. Clinical management (therapy received including antibiotics, bronchodilators and oxygen therapy) and outcomes (presence of danger signs, admission to ICU, duration of stay in hospital, discharge outcome, and final diagnosis) were recorded.

Study assays and measurement for vitamin D

Sera from venous blood were assayed at Metabolomics Australia, Centre for Microscopy, Characterization, and Analysis, University of Western Australia, Perth. The total serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 concentrations were measured using liquid chromatography-tandem mass spectrometry using an Agilent 6460 2D LC-MS/MS, Singapore. This was the current gold standard for vitamin D measurement, which has shown excellent agreement with CDC’s 25(OH)D3 inaugural vitamin D standardization program (r2 = 0.99) [26]. The limit of detection and the limit of quantitation of the assay for 25-hydroxyvitamin D3 is 0.5 nM and 2 nmol/L, consecutively.

Sample size calculation

We expected at least 25–70 admissions in each of the two hospitals for pneumonia in under five years old children over the one-year recruitment period. Based on a 10% refusal rate, at least 128 participants enabled description of the prevalence of vitamin D in under-five children admitted for pneumonia to within 8.7% based on an estimated prevalence of 40% (as estimated from community-based studies), based on a two-sided 95% confidence interval.

Statistical analysis

Data were double entered to REDCap from data collection instruments and exported to STATA version 15 (Stata Corporation, College Station, Texas) for analysis. Continuous variables were presented as mean ±SD for normal distribution or median and interquartile range for skewed variables. Categorical variables were presented as proportions (%). Vitamin D levels were summarized as continuous and categorical variables.

Indicators of the severity of pneumonia for analysis were presence or absence of danger signs, hypoxemia, prolonged hospitalization, and ICU admission. Binomial categorization of vitamin D was used in the univariate and multivariate logistic regression analysis for exploring the association between vitamin D status and the indicators of severity of pneumonia as binary variables. Results were presented as Odds ratios (ORs) with 95% CIs. A p-value of < 0.05 was considered statistically significant.

Ethics

Ethics approvals for the study were obtained through the UGM Medical and Health Research Ethics Committee (MHREC), Yogyakarta, Indonesia (ethic approval number KE/FK/935/EC/2015) and the University of Melbourne Human Research Committee (ethics approval number 1544817).

Results

From 1st February 2016 to 31st July 2017, there were 110 out of 286 (39%) and 23 out of 77 (30%) of children admitted with a diagnosis of pneumonia in the rural and the urban hospitals, respectively, that were eligible for recruitment and enrolled in the study (Fig 1). Of these, 127 (96%) had vitamin D results available for analysis. No mortality was reported but two ICU admissions were documented.

Fig 1. Hospital study recruitment between the 1st February 2016 to 31th July 2017.

Fig 1

The median age of participants was 12 (IQR 6–23) months old with the majority of participants from the rural hospital (83%) and of male sex (59%). Sixty-two (47%) of participants were exclusively breastfed until six months and 24 (18%) were aged less than six months at the time of recruitment and were still exclusively breastfed. The mean age of mothers was 32 (SD± 6.4) years and participants were predominantly from low-income families and around one half (52%) had a father who smoked cigarettes (Table 1).

Table 1. Baseline demographics of participants (N = 133)1.

Variables n (%)2
Characteristics of participants
Gender (male)—n (%) 79 (59%)
Location- n (%)
    Rural (Wates hospital) 110 (83%)
    Urban (Kota Yogyakarta hospital) 23 (17%)
Age (in months)—n (%), N = 132
    2–5 32 (24%)
    6–11 38 (29%)
    12–23 31 (24%)
    24–59 31 (24%)
Birth weight (in grams), median (IQR), N = 124 3000 (2775–3300)
    Normal (2500–4200 g) 112 (90%)
    Low (1500 –<2500 g) 10 (8%)
    Very low < 1500 g 2 (2%)
Exclusive breast feeding (EBF)—n (%), N = 111
    No 25 (23%)
    EBF until 6 months of age, now completed 62 (56%)
    ongoing EBF, in participants currently age ≤ 6 months 24 (22%)
Age started formula feeding (in months), median (IQR), N = 123 6 (2–12)
Solid food introduced before 6 months of age- n (%), N = 123 20 (16%)
Socio-environmental characteristics
Mother’s age- n (%), N = 123
    < 25 years old 16 (13%)
    25–29 years old 35 (29%)
    30–34 years old 27 (22%)
    35–39 years old 32 (26%)
    ≥ 40 years old 13 (11%)
Mother educational level—n (%), n = 126
    Completed middle school or less 47 (37%)
    Completed high school 63 (50%)
    Attended University 16 (13%)
Family income per month—n (%), n = 126
    IDR < = 1000K 87 (69%)
    > IDR 1000 K to < IDR 5000K 36 (29%)
    > IDR 5000K 3 (2%)
Solid fuel—n (%) 62 (47%)
Father daily smoker—n (%), n = 126
    No or occasionally 61 (48%)
    Yes, daily 65 (52%)

1 N = 133 throughout table, unless otherwise specified.

2 variables were presented as n (%) for categorical, mean (±SD) for parametric and median (interquartile range) for non- parametric variables.

1 USD is ~15,000 IDR.

Fast breathing was the most common presenting symptoms (95%), followed by fever (78%) (Table 2). Chest indrawing was present in 84% of participants and 14% of participants were hypoxemic on admission, although 80% of all recruited participants received oxygen therapy. Thirty participants (23%) were underweight or severely underweight (based on weight for age < -2 SD), and of the 70 participants with weight-for length recorded, 14 (20%) were wasted or severely wasted.

Table 2. Clinical characteristics and laboratory profiles of participants (n = 133)1.

Clinical characteristics n (%)2
Symptoms and signs—n (%)
    Fever 104 (78%)
    Cough 133 (100%)
    Runny nose 83 (62%)
    Wheezing, N = 132 74 (56%)
    Fast breathing, N = 132 126 (95%)
    Chest indrawing, N = 132 111 (84%)
    Stridor 16 (12%)
    Any danger signs on admission 38 (29%)
Clinical case definition for pneumonia—n (%) 133 (100%)
    Non-severe pneumonia 95 (71%)
    Severe pneumonia3 38 (29%)
Oxygen saturation on admission (in %), median (IQR), n = 125 94 (92–97)
Level of oxygen saturation on admission4 - n (%), N = 125
    ≥ 90% 107 (81%)
    < 90% 18 (14%)
Length of stay (in days), median (IQR) 5 (4–6)
Prolonged stay (> 5 days)—n (%) 49 (37%)
Weight for age—n (%)
    Normal (-2SD to 2 SD) 100 (75%)
    Underweight (- 3 SD to < -2 SD) 18 (14%)
    Severely underweight (< -3 SD) 12 (9%)
    > 2 SD 2 (2%)
Length for age—n (%), N = 69
    Normal (-2SD to 2 SD) 42 (61%)
    Stunted (- 3 SD to < -2 SD) 17 (25%)
    Severely stunted (< -3 SD) 8 (12%)
    Tall > 2 SD 2 (3%)
Weight for length—n (%), N = 70
    Normal (-2SD to 2 SD) 51 (73%)
    Wasted (- 3 SD to < -2 SD) 9 (13%)
    Severely Wasted (< -3 SD) 5 (7%)
    Overweight > 2 SD 5 (7%)
Anemia—n (%)5 57 (43%)
Leukocytosis—n (%)6 105 (79%)
Neutrophilia—n (%)7, N = 132 25 (19%)
Lymphocytosis—n (%)8 63 (47%)

1 N = 133 throughout table, unless otherwise specified.

2 Variables were presented as N (%) for categorical, mean (±SD) for parametric and median (interquartile range) for non- parametric variables.

3severe pneumonia according to WHO 2014 is cough with fast breathing and/or chest indrawing with any danger sign.

4hypoxaemia indicated by oxygen saturation < 90%.

5Anemia was defined as hemoglobin concentration of < 12.6 gram/dL in age under 6 months, < 12 gram/dL in age between 6 and 23 months, and < 12.5 gram/dL in between 24–59 months.

6 Leukocytosis was defined as if white blood count > 11.9 x 103 in children aged < 6 mo, > 10.6 x 103 in children aged 6–23 months and >8.5 x 103 in children aged 24–59.

7Netrophilia was defined as neutrophil count >70% of the total leucocytes on a peripheral blood smear.

8lympocytosis was defined as lymphocytes count >40% of the total leucocytes on a peripheral blood smear.

The vitamin D level was normally distributed (Fig 2) (mean (± SD): 67 ± 24 nmol/L) with 19% (25/127) of participants having serum vitamin D less than 50 nmol/L. Of these vitamin D-deficient participants, 36% (9/25) had serum vitamin D level less than 30 nmol/L.

Fig 2. The distribution of serum vitamin D level on admission.

Fig 2

Vitamin D deficiency was not associated with the presence of danger signs, the duration of stay in the hospital and hypoxemia (Table 3). A sensitivity analysis using a higher and a lower vitamin D cut off (< 75 nmol/L and <25 nmol/L) did not alter the findings (Table 3). Participants younger than six months were twice as likely to have prolonged hospitalization compared to older participants (AOR 2.91, 95% CI: 1.23–6.92, Table 3). Low birth weight and poor nutritional status on admission were significant independent risk factors for hypoxemia on admission in the hospital.

Table 3. Risk factors for severe pneumonia (presence of danger signs, hypoxemia, prolonged stay).

With danger signs Hypoxemia Prolonged stay
Characteristics Adjusted OR1 p-value Adjusted OR1 p- value Adjusted OR1 p-value
Vitamin D level
    < 75 nmol/L2 1.04 (0.38–2.86) 0.94 1.47 (0.34–6.31) 0.61 0.61 (0.25–1.51) 0.28
    < 50 nmol/L2 0.80 (0.25–2.56) 0.71 1.34 (0.29–6.13) 0.70 0.72 (0.25–2.08) 0.55
    < 25 nmol/L2 1.10 (0.20–5.95) 0.92 6.41 (0.77–53.34) 0.09 1.10 (0.20–5.95) 0.92
Younger age (2–5 months old) 1.53 (0.61–3.85) 0.36 0.77 (0.20–3.01) 0.71 2.91 (1.23–6.91) 0.02
Younger Gestational age (in weeks) 1.11 (0.93–1.31) 0.26 1.34 (1.07–1.67) 0.01 0.99 (0.84–1.16) 0.88
Low birth weight (< 2500 g) 1.28 (0.35–4.67) 0.71 4.59 (1.14–18.50) 0.03 1.09 (0.33–3.68) 0.89
Increased maternal age 0.99 (0.92–1.06) 0.69 1.02 (0.93–1.11) 0.72 0.97 (0.91–1.03) 0.30
Weight for age
    -2 SD to 2 SD Ref Ref Ref
    < - 2SD (underweight) 0.94 (0.27–3.25) 0.92 5.95 (1.54–23.04) 0.01 1.55 (0.52–4.62) 0.43
    < - 3SD (severely underweight) 0.93 (0.21–4.16) 0.92 9.58 (1.46–62.34) 0.02 8.53 (1.89–38.49) 0.005
Weight/length for age
    > 2 SD 3.14 (0.35–28.56) 0.31 n/a 1.88 (0.22–16.49) 0.57
    -2 SD to 2 SD Ref Ref Ref
    < - 2SD (wasted) 1.81 (0.35–9.42) 0.48 11.26 (0.86–147.47) 0.07 1.38 (0.27–6.94) 0.70
    < - 3SD (severely wasted) 2.36 (0.29–18.86) 0.42 n/a 2.89 (0.40–20.75) 0.29
Early introduction of solid foods3 2.45 (0.86–6.92) 0.09 1.91 (0.51–7.10) 0.34 0.45 (0.15–1.37) 0.16
Anemia4 1.00 (0.37–2.72) 0.99 2.00 (0.42–9.66) 0.39 0.93 (0.38–2.23) 0.86
Received antibiotics prior to admission 0.89 (0.35–2.28) 0.81 0.33 (0.09–1.28) 0.11 0.45 (0.20–1.04) 0.06

1Adjusted for gender, passive smoking exposure, socio-economic status, overcrowding house.

2Adjusted for ender, passive smoking exposure, socio-economic status, overcrowding house, and exclusive breastfeeding status.

3 Solids given before 6 months.

4Anemia was defined as hemoglobin concentration of < 12.6 gram/dL in age under 6 months, < 12 gram/dL in age between 6 and 23 months, and < 12.5 gram/dL in between 24–59 months.

n/a–there was no sufficient number to run the analysis for the association between exposure and outcome.

Discussion

We found that one in every five children aged 2–59 months admitted to hospital with pneumonia was vitamin D deficient (<50 nmol/L), but vitamin D status was not associated with the severity of pneumonia as indicated by the presence of danger signs, hypoxemia or prolonged hospitalization.

The prevalence of vitamin D deficiency in young children hospitalized with pneumonia in low-middle income countries (LMICs) has been reported to be between 12% to 63% [5,27,28], compared with 9.7% to 30% in high income countries [18,19,29]. Our finding of 19% is similar to that reported in children from Nepal hospitalized with WHO-defined pneumonia (12% of 568 children studied), with comparable demographic profiles but a higher proportion of participants with danger signs or hypoxemia than in our study [17]. A study from Yemen reported a higher prevalence (37%, 29/79) of vitamin D deficiency in children under five years with very severe pneumonia using a lower cut off (< 30 nmol/L), with more than three-quarter of vitamin D deficient participants being clinically rachitic [28]. There are a range of environmental and individual factors that determine vitamin D status that may explain variations of prevalence between settings and populations [30].

Similar to our findings, some observational studies have found that serum vitamin D level on admission was not associated with the severity of pneumonia [19,31,32], while other studies have reported that vitamin D deficiency (< 50 nmol/L) was significantly associated with a higher likelihood for ICU admission, treatment failure, or longer hospital stay [17,18,33]. Studies that reported a significant association had small sample sizes [18,33], did not adjust for confounders [33] or had wide confidence intervals [18], limiting statistical interpretation [33]. While many of our study participants received oxygen therapy, in a subgroup analysis limited to those with hypoxemia, we did not identify an association between vitamin D level and the duration of oxygen therapy received.

There have been few clinical trials on supplementation of vitamin D for severe pneumonia in hospital settings [15]. Oral vitamin D supplementation 1000–2000 IU/day for 5 days in Indian children (age 2 to 59 months) hospitalized with pneumonia was not associated with the resolution time from pneumonia as indicated by the disappearance of chest indrawing and/or danger signs, and hours of hospital stay, but the sample size was small (N = 20) [34]. On the contrary, a higher single dose of oral vitamin D (100,000 IU) was effective to prevent from pneumonia recurrency within 90 days in Afghan children with non-severe pneumonia (N = 453, age 1 to 36 months) but a similar dose of vitamin D supplementation given quarterly in healthy infants in the same population (N = 3,046) did not show prevention from getting pneumonia [35,36]. Different doses of vitamin D tested, and parameters of pneumonia severity have contributed to inconsistent results between trials, and it is difficult to interpret the effect of vitamin D on pneumonia severity based on the assessment of a singular study. A more comprehensive analysis for multiple studies in a Cochrane meta-analysis study of seven randomized controlled trials (N = 1,529 participants) published in 2018, reported that vitamin D supplementation (doses 1000 IU to 100,000 IU) in children hospitalized with severe pneumonia did not impact the time to resolution, duration of hospitalization, or mortality rate [15]. The small number and poor quality of trial data in the meta-analysis were of concern. Recently published trials were also dealt with small sample sizes and methodological issues [14,16,37,38].

Results are pending from at least ten vitamin D clinical trials on childhood respiratory infections from Northern Australia, India, New Zealand, Bangladesh, Iran, Chile, and South Africa [39]. These studies include a range of outcome measure including recurrent infection, duration of stay, admission to ICU, respiratory distress and mortality compared between study participants receiving vitamin D supplementation and placebo [39]. In combination with our study these data will provide an improved understanding of the impact of vitamin D deficiency on the severity of hospitalized childhood pneumonia globally, and the potential role of vitamin D supplementation to reduce pneumonia severity [14]. Larger numbers of trials available for meta-analysis are required to give a more definite answer on the impact of the intervention and inform clinical and public health policy and practice.

We found that young age (<6 months) and low birth weight and poor nutritional status on admission were risk factors for severe pneumonia, consistent with findings from other studies [40,41]. Undernutrition is well known to be associated with the frequency, severity, and mortality of pneumonia due to the weakened host defense mechanisms against infections and decreased respiratory muscles functions [4245]. Even in vaccinated individuals, malnutrition is associated with a reduction of immunogenicity post-vaccinations [44]. There is a vicious cycle of poor nutritional status and infections [42,43]. While malnutrition decreases innate and adaptive immune functions and increases susceptibility to infections, infections themselves are associated with reduced intake and malabsorption of nutrients due to mucosal injury and altered gut lumens [43]. Low birth weight is also a known risk factor for malnutrition in later childhood [43] as found in our study.

The relationship between vitamin D and inflammation is not completely understood. There have been conflicting data on the role vitamin D deficiency may play on acute and resolving respiratory infection with one study reported that vitamin D status was unlikely to be altered during the acute and recovery phase whereas another study reported that vitamin D deficiency could be a consequence of acute and chronic inflammation [46,47]. It has been hypothesized that vitamin D modulates the host defense mechanism to control the immune response, including the suppression of inflammatory cytokines expressions that can contribute to life-threatening lung inflammation and impaired oxygenation [48,49]. Cathelicidin is an antimicrobial peptide that serve as the direct target gene of vitamin D receptors and is associated with an up-regulation of pathogen clearance [50,51]. However, in a randomized controlled trial in children in India with more than 30% participants had vitamin D level < 37.5 nmol/L, high dose vitamin D administration of 100,000 IU did not confirm significant clinical benefit or confer alteration of serum cathelicidin expression in two week following supplementation [50]. A case control study of 80 Egyptian children demonstrated a positive correlation between serum vitamin D level and cathelicidin levels in case group (mean serum vitamin D 34.87±16.6 nmol/L, r > 0.60) which both serum parameters were measured on the admission day [52]. The timing of vitamin D and cathelicidin measurements in both studies were different which may reflect different cathelicidin expression.

Limitations of our study included the small sample size which may have diminished the power to detect an association between vitamin D deficiency and pneumonia severity. Further, few of our participants presented with danger signs, including hypoxemia. Future studies in the population with a high prevalence of severe pneumonia, i.e., significant proportion of young children with hypoxemia, ICU admission or treatment failure to first line antibiotics, should be considered. We did not investigate the etiology of pneumonia that might have considerable impact on pneumonia severity. Strengths of the study included a recruitment period of over 12 months enabled us to include both seasons, wet and dry. This is important as both respiratory infection and vitamin D are deemed to be seasonal. A standardized of serum vitamin D measurement was employed in our study and we tested different cut off vitamin D levels for association with pneumonia severity in the analysis.

Conclusion

Vitamin D deficiency was common in under-five children hospitalized with pneumonia but was not related to pneumonia severity and hospitalization outcomes. Data from ongoing clinical trials are needed for better elucidation of the effects of vitamin D supplementation on the severity of pneumonia, particularly in LMIC settings such as Indonesia.

Supporting information

S1 File. Study case report form and questionnaire.

(PDF)

Acknowledgments

We thank all participants and parents who participated to this study, all study site staffs and pediatricians from district hospitals in Kota Yogyakarta and Kulon Progo who helped with the study recruitment. Lastly, we especially thank to all IPADS research assistants who assisted with data collection and study conduct.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This study was supported by Murdoch Children's Research Institute in the form of funding awarded to SMG, Schlumberger foundation faculty for the future in the form of funding awarded to VO, Indonesia Endowment Fund for Education (LPDP) Ministry of Finance in the form of a grant awarded to VO (20130822080370), the David Bickart Clinician Research Fellowship from the University of Melbourne awarded to MD, Australia-Indonesia Centre (AIC) in the form of a grant awarded to MD and YS (01HSP1MELDancUGM003), and infrastructure funding from the Western Australian State Government, in partnership with the Australian Federal Government, through Bioplatforms Australia and the National Collaborative Research Infrastructure Strategy awarded to MWC. MCRI is supported by the Victorian Government Infrastructure Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med. 1990;323(3):160–4. doi: 10.1056/NEJM199007193230304 [DOI] [PubMed] [Google Scholar]
  • 2.Fawzi WW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child mortality. A meta-analysis. JAMA. 1993;269(7):898–903. [PubMed] [Google Scholar]
  • 3.UNICEF. One is too many: Ending child deaths from pneumonia and diarrhoea. New York, USA: UNICEF; 2016. [Google Scholar]
  • 4.Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators’ Collaborative Group. J Pediatr. 1999;135(6):689–97. doi: 10.1016/s0022-3476(99)70086-7 [DOI] [PubMed] [Google Scholar]
  • 5.Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatric research. 2017;82(6):986–93. doi: 10.1038/pr.2017.71 [DOI] [PubMed] [Google Scholar]
  • 6.Shin YH, Yu J, Kim KW, Ahn K, Hong SA, Lee E, et al. Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA). Korean J Pediatr. 2013;56(10):439–45. doi: 10.3345/kjp.2013.56.10.439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. The Lancet Global Health. 2019;7(1):e47–e57. doi: 10.1016/S2214-109X(18)30408-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Oktaria V, Graham SM, Triasih R, Soenarto Y, Bines JE, Ponsonby AL, et al. The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS One. 2020;15(10):e0239603. doi: 10.1371/journal.pone.0239603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tan KK, Dang DA, Kim KH, Kartasasmita C, Kim HM, Zhang XH, et al. Burden of hospitalized childhood community-acquired pneumonia: A retrospective cross-sectional study in Vietnam, Malaysia, Indonesia and the Republic of Korea. Hum Vaccin Immunother. 2017:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sandjaja, Budiman B, Harahap H, Ernawati F, Soekarti M, Widodo Y, et al. Food consumption and nutritional and biochemical status of 0.5–12 year old Indonesian children: the SEANUTS study. British Journal of Nutrition. 2013;110:S11–S20. doi: 10.1017/S0007114513002109 [DOI] [PubMed] [Google Scholar]
  • 11.Oktaria V, Danchin M, Triasih R, Soenarto Y, Bines JE, Ponsonby AL, et al. The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency. PLoS One. 2021;16(3):e0248722. doi: 10.1371/journal.pone.0248722 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12. doi: 10.4049/jimmunol.173.5.2909 [DOI] [PubMed] [Google Scholar]
  • 13.Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. doi: 10.1136/bmj.i6583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. Cochrane Database of Systematic Reviews. 2016(11). doi: 10.1002/14651858.CD008824.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database of Systematic Reviews. 2018(7). doi: 10.1002/14651858.CD011597.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Singh N, Kamble D, Mahantshetti NS. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children. Indian J Pediatr. 2019;86(12):1105–11. doi: 10.1007/s12098-019-03025-z [DOI] [PubMed] [Google Scholar]
  • 17.Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017. doi: 10.1038/pr.2017.71 [DOI] [PubMed] [Google Scholar]
  • 18.Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, et al. Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. J Pediatr. 2017;187:323–7. doi: 10.1016/j.jpeds.2017.04.061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Beigelman A, Castro M, Schweiger TL, Wilson BS, Zheng J, Yin-DeClue H, et al. Vitamin D Levels Are Unrelated to the Severity of Respiratory Syncytial Virus Bronchiolitis Among Hospitalized Infants. J Pediatric Infect Dis Soc. 2015;4(3):182–8. doi: 10.1093/jpids/piu042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.World Health Organization. Vitamin D supplementation and respiratory infections in children 2019 [updated 29 March 2019; cited 2020 21 may 2020]. Available from: https://www.who.int/elena/titles/vitamind_pneumonia_children/en/.
  • 21.World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva: WHO Press; 2014. Available from: http://apps.who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf. [PubMed]
  • 22.Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report. 2010(29):1–20, 4. [PubMed] [Google Scholar]
  • 23.Tiewsoh K, Lodha R, Pandey RM, Broor S, Kalaivani M, Kabra SK. Factors determining the outcome of children hospitalized with severe pneumonia. BMC Pediatr. 2009;9:15. doi: 10.1186/1471-2431-9-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.World health organization. Nutrition Landscape Information System (NLIS) country profile indicators: interpretation guide. Geneva, Switzerland: WHO Document Production Services,; 2010. Available from: https://www.who.int/nutrition/nlis_interpretation_guide.pdf. [Google Scholar]
  • 25.Paxton GA, Teale GR, Nowson CA, Mason RS, McGrath JJ, Thompson MJ, et al. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. Med J Aust. 2013;198(3):142–3. doi: 10.5694/mja11.11592 [DOI] [PubMed] [Google Scholar]
  • 26.Clarke M, Tuckey R, Gorman S, Holt B, Hart P. Optimized 25-hydroxyvitamin D analysis using liquid–liquid extraction with 2D separation with LC/MS/MS detection, provides superior precision compared to conventional assays. Metabolomics. 2013;9(1):1031–40. [Google Scholar]
  • 27.Velarde Lopez AA, Gerber JS, Leonard MB, Xie D, Schinnar R, Strom BL. Children with lower respiratory tract infections and serum 25-hydroxyvitamin D3 levels: A case-control study. Pediatr Pulmonol. 2016. doi: 10.1002/ppul.23439 [DOI] [PubMed] [Google Scholar]
  • 28.Banajeh SM. Nutritional rickets and vitamin D deficiency—association with the outcomes of childhood very severe pneumonia: a prospective cohort study. Pediatr Pulmonol. 2009;44(12):1207–15. doi: 10.1002/ppul.21121 [DOI] [PubMed] [Google Scholar]
  • 29.McNally JD, Leis K, Matheson LA, Karuananyake C, Sankaran K, Rosenberg AM. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatr Pulmonol. 2009;44(10):981–8. doi: 10.1002/ppul.21089 [DOI] [PubMed] [Google Scholar]
  • 30.Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. doi: 10.1056/NEJMra070553 [DOI] [PubMed] [Google Scholar]
  • 31.Iqbal S, Mosenkis EV, Jain P, Wiles A, Lerner J, Benton AS, et al. Vitamin d in pediatric inpatients with respiratory illnesses. Hosp Pediatr. 2013;3(4):371–6. doi: 10.1542/hpeds.2013-0001 [DOI] [PubMed] [Google Scholar]
  • 32.Sismanlar T, Aslan AT, Gulbahar O, Ozkan S. The effect of vitamin D on lower respiratory tract infections in children. Turk Pediatri Ars. 2016;51(2):94–9. doi: 10.5152/TurkPediatriArs.2016.3383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Inamo Y, Hasegawa M, Saito K, Hayashi R, Ishikawa T, Yoshino Y, et al. Serum vitamin D concentrations and associated severity of acute lower respiratory tract infections in Japanese hospitalized children. Pediatr Int. 2011;53(2):199–201. doi: 10.1111/j.1442-200x.2010.03224.x [DOI] [PubMed] [Google Scholar]
  • 34.Choudhary N, Gupta P. Vitamin D supplementation for severe pneumonia—a randomized controlled trial. Indian Pediatr. 2012;49(6):449–54. doi: 10.1007/s13312-012-0073-x [DOI] [PubMed] [Google Scholar]
  • 35.Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D, et al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010;15(10):1148–55. doi: 10.1111/j.1365-3156.2010.02578.x [DOI] [PubMed] [Google Scholar]
  • 36.Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379(9824):1419–27. doi: 10.1016/S0140-6736(11)61650-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kumar P, Goyal JP. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children—Correspondence 2. Indian J Pediatr. 2020;87(10):878. doi: 10.1007/s12098-020-03244-9 [DOI] [PubMed] [Google Scholar]
  • 38.Kumar J, Yadav A. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children—Correspondence 1. Indian J Pediatr. 2020;87(10):877. doi: 10.1007/s12098-020-03245-8 [DOI] [PubMed] [Google Scholar]
  • 39.World health Organization. International Clinical Trial registry Platform [cited 2020 09 June 2020]. Available from: https://apps.who.int/trialsearch/nutrition.aspx?Title=respiratory%20infection%20and%20vitamin%20D%20and%20children%20.
  • 40.Paynter S, Ware RS, Lucero MG, Tallo V, Nohynek H, Simoes EA, et al. Poor growth and pneumonia seasonality in infants in the Philippines: cohort and time series studies. PLoS One. 2013;8(6):e67528. doi: 10.1371/journal.pone.0067528 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Jackson S, Mathews KH, Pulanic D, Falconer R, Rudan I, Campbell H, et al. Risk factors for severe acute lower respiratory infections in children: a systematic review and meta-analysis. Croat Med J. 2013;54(2):110–21. doi: 10.3325/cmj.2013.54.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ginsburg AS, Izadnegahdar R, Berkley JA, Walson JL, Rollins N, Klugman KP. Undernutrition and pneumonia mortality. Lancet Glob Health. 2015;3(12):e735–6. doi: 10.1016/S2214-109X(15)00222-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008;46(10):1582–8. doi: 10.1086/587658 [DOI] [PubMed] [Google Scholar]
  • 44.Rytter MJ, Kolte L, Briend A, Friis H, Christensen VB. The immune system in children with malnutrition—a systematic review. PLoS One. 2014;9(8):e105017. doi: 10.1371/journal.pone.0105017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Chisti MJ, Tebruegge M, La Vincente S, Graham SM, Duke T. Pneumonia in severely malnourished children in developing countries—mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Trop Med Int Health. 2009;14(10):1173–89. doi: 10.1111/j.1365-3156.2009.02364.x [DOI] [PubMed] [Google Scholar]
  • 46.Haugen J, Chandyo RK, Ulak M, Mathisen M, Basnet S, Brokstad KA, et al. 25-Hydroxy-Vitamin D Concentration Is Not Affected by Severe or Non-Severe Pneumonia, or Inflammation, in Young Children. Nutrients. 2017;9(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013;66(7):620–2. doi: 10.1136/jclinpath-2012-201301 [DOI] [PubMed] [Google Scholar]
  • 48.Schaible B, Schaffer K, Taylor CT. Hypoxia, innate immunity and infection in the lung. Respir Physiol Neurobiol. 2010;174(3):235–43. doi: 10.1016/j.resp.2010.08.006 [DOI] [PubMed] [Google Scholar]
  • 49.Sassi F, Tamone C, D’Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients. 2018;10(11). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Gupta P, Dewan P, Shah D, Sharma N, Bedi N, Kaur IR, et al. Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial. Indian Pediatr. 2016;53(11):967–76. doi: 10.1007/s13312-016-0970-5 [DOI] [PubMed] [Google Scholar]
  • 51.Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–77. doi: 10.1096/fj.04-3284com [DOI] [PubMed] [Google Scholar]
  • 52.Albanna EAM, Ali YF, Reayid AM, Elkashnia. Vitamin D and LL-37 in children with pneumonia Egypt J Pediatr Allergy Immunol 2010;8(2):81–6. [Google Scholar]

Decision Letter 0

Michal Zmijewski

12 May 2021

PONE-D-21-03177

Vitamin D deficiency and severity of pneumonia in Indonesian children

PLOS ONE

Dear Dr. Oktaria,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michal Zmijewski

Academic Editor

PLOS ONE

Additional Editor Comments:

Please, consider some additional corrections:.

1. Information concerning vitamin D supplementation is missing.

2. I agree with reviewer one, please recalculate the data using 75 nmol/mL cutoff.

It would be informative to plot at least most impotent clinical data (severity, hypoxemia) against vitamin D concentration

and try to find out if very is any correlation.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include additional information regarding the parent-interview questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed the questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. If the questionnaire is published, please provide a citation to the (1) questionnaire and/or (2) original publication associated with the questionnaire.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript found that vitamin D deficiency was not associated with severity of pneumonia for infants in Indonesia. This finding is in general agreement with other studies.

One limitation of the manuscript is that no detailed information was given on the distribution of 25(OH)D concentrations. Perhaps a histogram could be supplied. Also, the use of 50 nmol/L was not justified. I understand that 50 nmol/L is normally considered the cutoff for vitamin D deficiency. However, there are different cutoffs of 25(OH)D for different health outcomes. The authors should try different cutoffs and find the one that yields the strongest correlation, perhaps also with the lowest 95% CI interval.

the total serum 25-

130 hydroxyvitamin D3 and 25-hydroxyvitamin D2 concentrations were measured using liquid

131 chromatography-tandem mass spectrometry

Comment: Please identify the instrument manufacturer and city, (state) and country.

Additional papers to consider citing as found by searching scholar.google.com with “pneumonia infants vitamin D”. The authors might search there further.

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency.

Oktaria V, Danchin M, Triasih R, Soenarto Y, Bines JE, Ponsonby AL, Clarke MW, Graham SM.PLoS One. 2021 Mar 23;16(3):e0248722. doi: 10.1371/journal.pone.024872

Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial.

Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, Walraven G, Chandramohan D.Lancet. 2012 Apr 14;379(9824):1419-27. doi: 10.1016/S0140-6736(11)61650-4.

Vitamin D supplementation for severe pneumonia--a randomized controlled trial.

Choudhary N, Gupta P.Indian Pediatr. 2012 Jun;49(6):449-54. doi: 10.1007/s13312-012-0073-x. E

Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children.

Singh N, Kamble D, Mahantshetti NS.Indian J Pediatr. 2019 Dec;86(12):1105-1111. doi: 10.1007/s12098-019-03025-z

Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children - Correspondence 2.

Kumar P, et al. Indian J Pediatr. 2020. PMID: 32170491 No abstract available.

Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children - Correspondence 1.

Kumar J, et al. Indian J Pediatr. 2020. PMID: 32172465 No abstract available.

Vitamin D Status in Neonatal Pulmonary Infections: Relationship to Inflammatory Indicators.

El-Kassas GM, El Wakeel MA, Elabd MA, Kamhawy AH, Atti MA, El-Gaffar SAA, Hanafy SK, Awadallah E.Open Access Maced J Med Sci. 2019 Dec 14;7(23):3970-3974. doi: 10.3889/oamjms.2019.592.

Vitamin D and LL-37 in children with pneumonia

EAM Albanna, YF Ali, RAM Elkashnia - Egyptian Journal of Pediatric …, 2010 - ajol.info

… tract infection (77.0 nmol/l) and hospital controls (77.2 nmol/l), the average vitamin D status of

these individuals was greater than 75 nmol/l, which can be explained by that all the studied infants

consumed vitamin D through fortified infant formula or … Pneumonia …

  Cited by 19 Related articles All 5 versions 

https://www.ajol.info/index.php/ejpai/article/view/108522

Is anything known about the source of the pneumonia, i.e., bacterial, fungal, or viral?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jul 9;16(7):e0254488. doi: 10.1371/journal.pone.0254488.r002

Author response to Decision Letter 0


24 Jun 2021

PONE-D-21-03177

Vitamin D deficiency and severity of pneumonia in Indonesian children

Response to the reviewers

Academic editors

1. Information concerning vitamin D supplementation is missing

Authors’ response

We have added more information relevant to vitamin D supplementation trials in the discussion section.

In our study participants, routine vitamin D supplementation in under five children was not a standard practice during our data collection. We did not collect information on vitamin D supplementation in our participants.

Change made in the manuscript

There have been few clinical trials on supplementation of vitamin D for severe pneumonia in hospital settings [15]. Oral vitamin D supplementation 1000 - 2000 IU/day for 5 days in Indian children (age 2 to 59 months) hospitalized with pneumonia was not associated with the resolution time from pneumonia as indicated by the disappearance of chest indrawing and/or danger signs, and hours of hospital stay, but the sample size was small (N=20) [34]. On the contrary, a higher single dose of oral vitamin D (100,000 IU) was effective to prevent from pneumonia recurrency within 90 days in Afghan children with non-severe pneumonia (N= 453, age 1 to 36 months) but a similar dose of vitamin D supplementation given quarterly in healthy infants in the same population (N=3,046) did not show prevention from getting pneumonia [35, 36]. (Line 285 - 294, Page 16)

2. I agree with reviewer one, please recalculate the data using 75 nmol/mL cut-off. It would be informative to plot at least most impotent clinical data (severity, hypoxemia) against vitamin D concentration and try to find out if very is any correlation.

Authors’ response

Thank you for highlighting this point. We have performed additional data analysis and tested different level of vitamin D cut-off (< 75 nmol/L, < 50 nmol/L, and < 25 nmol/L). However, the changes of cut offs did not materially change the overall results and conclusion (Table 3, Page 13-14)

Change made in the manuscript

There is no consensus on the recommended serum vitamin D cut off for respiratory health. We defined vitamin D deficiency as a serum (or plasma) 25-hydroxyvitamin D (25(OH)D) concentrations < 50 nmol/L. This is the recommended cut off for optimal bone homeostasis [25]. In this paper, we mainly used < 50 nmol as the cut-off for deficiency but different cut off levels (< 75 nmol/L and < 25 nmol/L) were also tested in our analysis. (Line 136 -141, Page 6)

For additional analysis results, please see changes in Table 3 (Page 13-14).

3. Please include additional information regarding the parent-interview questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed the questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. If the questionnaire is published, please provide a citation to the (1) questionnaire and/or (2) original publication associated with the questionnaire.

Authors’ response

We have attached our study questionnaire and case report forms in two language versions (S1 File)

Change made in the manuscript

Please see S1 File

Reviewer #1:

1. This manuscript found that vitamin D deficiency was not associated with severity of pneumonia for infants in Indonesia. This finding is in general agreement with other studies. One limitation of the manuscript is that no detailed information was given on the distribution of 25(OH)D concentrations. Perhaps a histogram could be supplied. Also, the use of 50 nmol/L was not justified. I understand that 50 nmol/L is normally considered the cutoff for vitamin D deficiency. However, there are different cutoffs of 25(OH)D for different health outcomes. The authors should try different cutoffs and find the one that yields the strongest correlation, perhaps also with the lowest 95% CI interval.

Authors’ response

We have provided an additional figure (histogram) in the manuscript (Fig 2. The distribution of serum vitamin D level on admission).

We have also performed additional data analysis and tested different level of vitamin D cut-off (< 75 nmol/L, < 50 nmol/L, and < 25 nmol/L). However, the changes of cut offs did not materially change the overall results and conclusion (Table 3, Page 13-14)

Change made in the manuscript

There is no consensus on the recommended serum vitamin D cut off for respiratory health. We defined vitamin D deficiency as a serum (or plasma) 25-hydroxyvitamin D (25(OH)D) concentrations < 50 nmol/L. This is the recommended cut off for optimal bone homeostasis.(Paxton et al. 2013) In this paper, we mainly used < 50 nmol as the cut-off for deficiency but different cut off levels (< 75 nmol/L and < 25 nmol/L) were also tested in our analysis. (Line 136 - 141, Page 6)

For additional analysis results, please see changes in Table 3 (Page 13-14).

2. The total serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 concentrations were measured using liquid chromatography-tandem mass spectrometry

Comment: Please identify the instrument manufacturer and city, (state) and country.

Authors’ response

We have added information on instrument manufacturer and city, (state) and country in the manuscript.

Change made in the manuscript

Sera from venous blood were assayed at Metabolomics Australia, Centre for Microscopy, Characterization, and Analysis, University of Western Australia, Perth. The total serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 concentrations were measured using liquid chromatography-tandem mass spectrometry using an Agilent 6460 2D LC-MS/MS, Singapore. This was the current gold standard for vitamin D measurement, which has shown excellent agreement with CDC’s 25(OH)D3 inaugural vitamin D standardization program (r2 =0.99).[23] The limit of detection and the limit of quantitation of the assay for 25-hydroxyvitamin D3 is 0.5 nM and 2 nmol/L, consecutively. (Line 159 - 166, Page 7)

3. Additional papers to consider citing as found by searching scholar.google.com with “pneumonia infants vitamin D”. The authors might search there further.

a. The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency. Oktaria V, Danchin M, Triasih R, Soenarto Y, Bines JE, Ponsonby AL, Clarke MW, Graham SM.PLoS One. 2021 Mar 23;16(3):e0248722. doi: 10.1371/journal.pone.024872

b. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, Walraven G, Chandramohan D.Lancet. 2012 Apr 14;379(9824):1419-27. doi: 10.1016/S0140-6736(11)61650-4.

c. Vitamin D supplementation for severe pneumonia--a randomized controlled trial. Choudhary N, Gupta P.Indian Pediatr. 2012 Jun;49(6):449-54. doi: 10.1007/s13312-012-0073-x. E

d. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children. Singh N, Kamble D, Mahantshetti NS.Indian J Pediatr. 2019 Dec;86(12):1105-1111. doi: 10.1007/s12098-019-03025-z

e. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children - Correspondence 2.

f. Kumar P, et al. Indian J Pediatr. 2020. PMID: 32170491 No abstract available. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children - Correspondence 1.

g. Kumar J, et al. Indian J Pediatr. 2020. PMID: 32172465 No abstract available.

h. Vitamin D Status in Neonatal Pulmonary Infections: Relationship to Inflammatory Indicators. El-Kassas GM, El Wakeel MA, Elabd MA, Kamhawy AH, Atti MA, El-Gaffar SAA, Hanafy SK, Awadallah E.Open Access Maced J Med Sci. 2019 Dec 14;7(23):3970-3974. doi: 10.3889/oamjms.2019.592.

i. Vitamin D and LL-37 in children with pneumonia. EAM Albanna, YF Ali, RAM Elkashnia - Egyptian Journal of Pediatric …, 2010 - ajol.info… tract infection (77.0 nmol/l) and hospital controls (77.2 nmol/l), the average vitamin D status of these individuals was greater than 75 nmol/l, which can be explained by that all the studied infants consumed vitamin D through fortified infant formula or … Pneumonia …

Authors’ response

Thank you very much for the suggestions. We have included some of those articles in the manuscript text as appropriate. Please see the changes throughout the manuscripts.

Changes in the manuscript

a. Community acquired pneumonia accounted for 18% of all hospitalizations in Indonesian children < 5 years with a case fatality rate between 5% and 20% [9]. Vitamin D deficiency has been reported common in one in every three to five Indonesian children aged between 6 months to 12 years old, and nine in every ten newborns [10, 11]. (Line 72-76, Page 4)

b. Vitamin D deficiency at birth has also been associated with more frequent episodes of acute respiratory infections non pneumonia in the first year of life of Indonesian infants [11]. (Line 80-82, Page 4)

c. There have been few clinical trials on supplementation of vitamin D for severe pneumonia in hospital settings [15]. Oral vitamin D supplementation 1000 - 2000 IU/day for 5 days in Indian children (age 2 to 59 months) hospitalized with pneumonia was not associated with the resolution time from pneumonia as indicated by the disappearance of chest indrawing and/or danger signs, and hours of hospital stay, but the sample size was small (N=20) [34]. On the contrary, a higher single dose of oral vitamin D (100,000 IU) was effective to prevent from pneumonia recurrency within 90 days in Afghan children with non-severe pneumonia (N= 453, age 1 to 36 months) but a similar dose of vitamin D supplementation given quarterly in healthy infants in the same population (N=3,046) did not show prevention from getting pneumonia [35, 36]. Different doses of vitamin D tested, and parameters of pneumonia severity have contributed to inconsistent results between trials, and it is difficult to interpret the effect of vitamin D on pneumonia severity based on the assessment of a singular study. A more comprehensive analysis for multiple studies in a Cochrane meta-analysis study of seven randomized controlled trials (N=1,529 participants) published in 2018, reported that vitamin D supplementation (doses 1000 IU to 100,000 IU) in children hospitalized with severe pneumonia did not impact the time to resolution, duration of hospitalization, or mortality rate [15]. The small number and poor quality of trial data in the meta-analysis were of concern. Recently published trials were also dealt with small sample sizes and methodological issues [14, 16, 37, 38]. (Line 285 - 303, Page 16)

d. However, in a randomized controlled trial in children in India with more than 30% participants had vitamin D level < 37.5 nmol/L, high dose vitamin D administration of 100,000 IU did not confirm significant clinical benefit or confer alteration of serum cathelicidin expression in two week following supplementation [50]. A case control study of 80 Egyptian children demonstrated a positive correlation between serum vitamin D level and cathelicidin levels in case group (mean serum vitamin D 34.87±16.6 nmol/L, r > 0.60) which both serum parameters were measured on the admission day [52]. The timing of vitamin D and cathelicidin measurements in both studies were different which may reflect different cathelicidin expression. (Line 352 - 360, Page 17 - 18)

4. Is anything known about the source of the pneumonia, i.e., bacterial, fungal, or viral?

Authors’ response

Unfortunately, we did not collect information on the pathogens causing pneumonia and it was not a routine procedure in the district hospitals in our settings.

We have stated this in the study limitation “We did not investigate the etiology of pneumonia that might have considerable impact on pneumonia severity”. (Line 367 -368, Page 18)

Change in the manuscript

None

Attachment

Submitted filename: Response to the reviewers.docx

Decision Letter 1

Michal Zmijewski

29 Jun 2021

Vitamin D deficiency and severity of pneumonia in Indonesian children

PONE-D-21-03177R1

Dear Dr. Oktaria,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michal Zmijewski

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for addressing all questions raised by reviewers.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Michal Zmijewski

1 Jul 2021

PONE-D-21-03177R1

Vitamin D deficiency and severity of pneumonia in Indonesian children

Dear Dr. Oktaria:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michal Zmijewski

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Study case report form and questionnaire.

    (PDF)

    Attachment

    Submitted filename: Response to the reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES